Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 8Recruiting 4Terminated 3Withdrawn 2Not yet recruiting 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neutropenia 1Infections 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Vancomycin × Clear all
NCT04025567 2020-03-16

Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT00296049 2018-08-10

Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy

Wake Forest University Health Sciences

Phase NA Withdrawn

Infections, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡